Progress on the Induction of Neutralizing Antibodies Against HIV Type 1 (HIV-1)

Overview

Journal BioDrugs

Specialties Allergy & Immunology
Genetics
Pharmacology

Date 2009 Jul 25

PMID 19627166

Citations 6

Authors

Michael Vaine

Shan Lu

Shixia Wang

Affiliations

Soon will be listed here.

Abstract

Infection with HIV type 1 (HIV-1), the causative agent of AIDS, is one of the most catastrophic pandemics to affect human healthcare in the latter 20th century. The best hope of controlling this pandemic is the development of a successful prophylactic vaccine. However, to date, this goal has proven to be exceptionally elusive. The recent failure of an experimental vaccine in a phase IIb study, named the STEP trial, intended solely to elicit cell-mediated immune responses against HIV-1, has highlighted the need for a balanced immune response consisting of not only cellular immunity but also a broad and potent humoral antibody response that can prevent infection with HIV-1. This article reviews the efforts made up to this point to elicit such antibody responses, especially with regard to the use of a DNA prime-protein boost regimen, which has been proven to be a highly effective platform for the induction of neutralizing antibodies in both animal and early-phase human studies.

Citing Articles

Toll-Like Receptor and Cytokine Responses to Infection with Endogenous and Exogenous Koala Retrovirus, and Vaccination as a Control Strategy.

Kayesh M, Hashem M, Tsukiyama-Kohara K Curr Issues Mol Biol. 2021; 43(1):52-64.

PMID: 33946297 PMC: 8928999. DOI: 10.3390/cimb43010005.

Koala retrovirus epidemiology, transmission mode, pathogenesis, and host immune response in koalas (Phascolarctos cinereus): a review.

Kayesh M, Hashem M, Tsukiyama-Kohara K Arch Virol. 2020; 165(11):2409-2417.

PMID: 32770481 PMC: 7413838. DOI: 10.1007/s00705-020-04770-9.

HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.

Gach J, Gorlani A, Dotsey E, Becerra J, Anderson C, Berzins B PLoS One. 2016; 11(8):e0160341.

PMID: 27500639 PMC: 4976892. DOI: 10.1371/journal.pone.0160341.

HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.

Malherbe D, Sanders R, van Gils M, Park B, Gomes M, Schuitemaker H PLoS One. 2013; 8(9):e75277.

PMID: 24040404 PMC: 3767832. DOI: 10.1371/journal.pone.0075277.

Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Pissani F, Malherbe D, Robins H, DeFilippis V, Park B, Sellhorn G Vaccine. 2012; 30(37):5519-26.

PMID: 22749601 PMC: 3447634. DOI: 10.1016/j.vaccine.2012.06.042.

References

Wang S, Chou T, Sakhatskyy P, Huang S, Lawrence J, Cao H . Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005; 79(3):1906-10. PMC: 544123. DOI: 10.1128/JVI.79.3.1906-1910.2005. View

Boyer J, Wang B, Ugen K, Agadjanyan M, Javadian A, Frost P . In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol. 1996; 25(3):242-50. DOI: 10.1111/j.1600-0684.1996.tb00022.x. View

Johnson W, Sanford H, Schwall L, Burton D, Parren P, Robinson J . Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol. 2003; 77(18):9993-10003. PMC: 224602. DOI: 10.1128/jvi.77.18.9993-10003.2003. View

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

Mascola J, Sambor A, Beaudry K, Santra S, Welcher B, Louder M . Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol. 2004; 79(2):771-9. PMC: 538538. DOI: 10.1128/JVI.79.2.771-779.2005. View

Wang R, Doolan D, Le T, Hedstrom R, Coonan K, Charoenvit Y . Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998; 282(5388):476-80. DOI: 10.1126/science.282.5388.476. View

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

Belshe R, Graham B, Keefer M, Gorse G, Wright P, Dolin R . Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA. 1994; 272(6):475-80. DOI: 10.1001/jama.272.6.475. View

Huang Z, Chou A, Tanguay J, Shen S, Mboudjeka I, Chou T . Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates. Curr HIV Res. 2008; 6(4):296-305. DOI: 10.2174/157016208785132518. View

10.

Kothe D, Decker J, Li Y, Weng Z, Bibollet-Ruche F, Zammit K . Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology. 2006; 360(1):218-34. PMC: 1945152. DOI: 10.1016/j.virol.2006.10.017. View

11.

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

12.

Selvarajah S, Puffer B, Lee F, Zhu P, Li Y, Wyatt R . Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses. 2008; 24(2):301-14. DOI: 10.1089/aid.2007.0158. View

13.

Li Y, Cleveland B, Klots I, Travis B, Richardson B, Anderson D . Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol. 2007; 82(2):638-51. PMC: 2224603. DOI: 10.1128/JVI.01691-07. View

14.

Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

15.

Pinter A, Honnen W, He Y, Gorny M, Zolla-Pazner S, Kayman S . The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol. 2004; 78(10):5205-15. PMC: 400352. DOI: 10.1128/jvi.78.10.5205-5215.2004. View

16.

Pantaleo G . HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect Dis. 2007; 8(2):82-3. DOI: 10.1016/S1473-3099(07)70266-9. View

17.

Hofmann-Lehmann R, Vlasak J, Rasmussen R, Jiang S, Li P, Baba T . Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol. 2002; 31(3):109-19. DOI: 10.1034/j.1600-0684.2002.01014.x. View

18.

Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S . The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine. 2008; 26(17):2100-10. PMC: 2790191. DOI: 10.1016/j.vaccine.2008.02.033. View

19.

Mulligan M, Russell N, Celum C, Kahn J, Noonan E, Montefiori D . Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses. 2006; 22(7):678-83. DOI: 10.1089/aid.2006.22.678. View

20.

Li Y, Migueles S, Welcher B, Svehla K, Phogat A, Louder M . Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med. 2007; 13(9):1032-4. PMC: 2584972. DOI: 10.1038/nm1624. View